Welcome to Helix Talk, an educational podcast for healthcare students and providers covering real-life clinical pearls, professional pharmacy topics, and drug therapy discussions.

This podcast is provided by pharmacists and faculty members at Rosal Franklin University College of Pharmacy.

This podcast contains general information for educational purposes only. This is not professional

advice and should not be used in lieu of obtaining advice from a qualified health care provider.

And now on to the show. Welcome to Helix Talk, episode 104. I'm your co-host Dr. Kane.

And I'm Dr. Patel. And in today's episode, we are discussing

what's the latest and the greatest from the Global Initiative for Asthma 2019 Guidelines.

The title of our talk today is breathtaking updates from Gina 2019. And just as a teaser for our

audience, we'll get to it later, but one of the biggest

changes in the Gina guidelines is actually challenging the role of albuterol as a rescue

inhaler.

So if you want to know more about that, stay tuned.

We'll get there.

But this is pretty groundbreaking recommendation from the GINA 2019 guidelines.

Yeah.

So we will in depth talk about it.

We have the references for the updated GINA guideline as well as not so updated 2007 NAEPP

guidelines too, which we practice in the United States. And then a couple of primary literature

that is associated with that change of al-Bur-Ral

Sabah as the rescue inhaler. So you will find those links on our podcast as well.

Cool. Well, just to kind of, you know, set the stage, if you will. So in terms of what is

asthma, asthma is really characterized by three different characteristics,

...